Glaukos Co. (NYSE:GKOS) Shares Sold by Truist Financial Corp

Truist Financial Corp decreased its holdings in Glaukos Co. (NYSE:GKOS) by 44.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,023 shares of the medical instruments supplier’s stock after selling 20,495 shares during the quarter. Truist Financial Corp’s holdings in Glaukos were worth $2,069,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. GAMMA Investing LLC purchased a new stake in Glaukos in the fourth quarter valued at about $55,000. Allspring Global Investments Holdings LLC boosted its stake in Glaukos by 17.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,827 shares of the medical instruments supplier’s stock worth $137,000 after purchasing an additional 270 shares in the last quarter. Mackenzie Financial Corp purchased a new stake in Glaukos during the 3rd quarter worth approximately $203,000. Xponance Inc. acquired a new position in Glaukos during the 3rd quarter valued at approximately $208,000. Finally, Pathstone Family Office LLC purchased a new position in shares of Glaukos in the third quarter worth $217,000. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

Glaukos Stock Up 0.7 %

GKOS opened at $107.64 on Friday. The company has a fifty day moving average of $94.66 and a two-hundred day moving average of $83.95. The company has a debt-to-equity ratio of 0.78, a quick ratio of 4.68 and a current ratio of 5.38. Glaukos Co. has a fifty-two week low of $54.38 and a fifty-two week high of $110.73. The stock has a market capitalization of $5.42 billion, a price-to-earnings ratio of -37.38 and a beta of 1.08.

Glaukos (NYSE:GKOS) last announced its quarterly earnings results on Wednesday, May 1st. The medical instruments supplier reported ($0.70) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.12). The business had revenue of $85.60 million during the quarter, compared to analysts’ expectations of $79.60 million. Glaukos had a negative net margin of 43.15% and a negative return on equity of 24.69%. Glaukos’s revenue for the quarter was up 15.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.59) EPS. On average, research analysts expect that Glaukos Co. will post -2.2 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. Jefferies Financial Group raised shares of Glaukos from a “hold” rating to a “buy” rating and boosted their price objective for the company from $84.00 to $125.00 in a report on Monday. StockNews.com cut Glaukos from a “hold” rating to a “sell” rating in a research note on Tuesday, February 27th. Mizuho lifted their target price on Glaukos from $85.00 to $100.00 and gave the stock a “neutral” rating in a report on Thursday, April 11th. JPMorgan Chase & Co. increased their price target on shares of Glaukos from $108.00 to $110.00 and gave the stock an “overweight” rating in a report on Thursday, May 2nd. Finally, BTIG Research lifted their price objective on shares of Glaukos from $107.00 to $112.00 and gave the company a “buy” rating in a research note on Thursday, May 2nd. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, Glaukos has a consensus rating of “Moderate Buy” and a consensus price target of $108.64.

Insider Transactions at Glaukos

In related news, Director Gilbert H. Kliman sold 5,000 shares of Glaukos stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $88.25, for a total value of $441,250.00. Following the sale, the director now owns 30,620 shares of the company’s stock, valued at approximately $2,702,215. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Glaukos news, CFO Alex R. Thurman sold 434 shares of the stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $95.33, for a total transaction of $41,373.22. Following the completion of the transaction, the chief financial officer now owns 54,166 shares of the company’s stock, valued at $5,163,644.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Gilbert H. Kliman sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $88.25, for a total value of $441,250.00. Following the completion of the transaction, the director now owns 30,620 shares in the company, valued at approximately $2,702,215. The disclosure for this sale can be found here. Insiders sold a total of 230,544 shares of company stock valued at $21,767,497 in the last three months. 6.40% of the stock is currently owned by company insiders.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.